Ken Griffin
CVKD icon

Ken Griffin’s Cadrenal Therapeutics CVKD Stock Holding History

Ken Griffin’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,864
Closed -$274K – 12851
2025
Q3 		$274K Buy
+19,864
New +$246K ﹤0.01% 10574
2024
Q3 		– Sell
-3,636
Closed -$25.6K – 14365
2024
Q2 		$25.6K Sell
3,636
-87
-2% -$602 ﹤0.01% 12421
2024
Q1 		$34.1K Buy
+3,723
New +$47.2K ﹤0.01% 12562
2023
Q4 		– Sell
-1,941
Closed -$19.8K – 14388
2023
Q3 		$19.8K Buy
+1,941
New +$27.6K ﹤0.01% 12637

Other funds holding CVKD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Ken Griffin's CVKD Position: Q4 2025 in Review

Ken Griffin sold out of Cadrenal Therapeutics (CVKD) in Q4 2025, closing a stake of 19,864 shares — an estimated $274K sold.

Ken Griffin first reported a position in CVKD in Q3 2023 and held it in 4 quarters. The position peaked at $274K in Q3 2025. 20 funds tracked by Wall St. Rank hold CVKD as of Q4 2025.

  • Ken Griffin reported no remaining Cadrenal Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Ken Griffin sold 19,864 Cadrenal Therapeutics shares in Q4 2025, an estimated $274K.
  • Ken Griffin first reported a position in Cadrenal Therapeutics in Q3 2023 and held it in 4 quarters.
  • Ken Griffin's Cadrenal Therapeutics position peaked at $274K in Q3 2025.
  • 20 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.